CT-132 statistically significantly reduced monthly migraine days compared with sham digital treatment after 12 weeks. The Food and Drug Administration (FDA) has granted marketing authorization to ...
Topiramate (Topamax) was initially developed for epilepsy, but doctors have been prescribing it for migraine prevention for decades. Discover its efficacy, safety info, and why it's earned the ...
Add Yahoo as a preferred source to see more of our stories on Google. If you've ever had a migraine, you know it's more than just a bad headache. The pounding pain, nausea and sensitivity can make it ...
Treatment with fremanezumab led to a significantly greater reduction in monthly migraine days and monthly headache days. The Food and Drug Administration (FDA) has approved Ajovy ® (fremanezumab-vfrm) ...
DENVER -- No new safety signals emerged with daily atogepant (Qulipta) for migraine prevention, an interim analysis of a long-term safety extension study showed, and improvements in efficacy were ...
The SPACE trial showed fremanezumab significantly reduced monthly migraine days in pediatric patients compared with placebo. The Food and Drug Administration (FDA) has accepted for review the ...
You don’t have to suffer an endless migraine attack. Learn the signs of status migrainosus, what treatments can break the ...
The National Headache Foundation (NHF) announced the release of a consensus statement aimed at migraine prevention as determined by an expert panel convened at the Migraine Prevention Summit, January ...
In the phase 3b ELEVATE trial, preventive treatment with atogepant (Qulipta) significantly reduced monthly migraine days compared to placebo in adults with episodic migraine in whom two to four ...
The American College of Physicians (ACP) issued a clinical guideline for episodic migraine prevention that varied from what migraine experts recommend. The ACP guideline, published in Annals of ...
Sally first sat in my chair years ago wanting to improve her smile. Then she disappeared. Not because anything went wrong.